Patents Assigned to Ma'at
  • SP35 Antibodies And Uses Thereof
    Publication number: 20170037126
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: July 20, 2016
    Publication date: February 9, 2017
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Methods of preventing and removing trisulfide bonds
    Patent number: 9562252
    Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: February 7, 2017
    Assignee: Biogen MA Inc.
    Inventors: Rashmi Rohit Kshirsagar, Alan Gilbert
  • ANTI-BCMA ANTIBODIES
    Publication number: 20170029518
    Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 2, 2017
    Applicant: Biogen MA Inc.
    Inventors: Susan L. Kalled, Yen-Ming Hsu
  • ATX modulating agents
    Patent number: 9555050
    Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: January 31, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Zhaohui Shao, Lihong Sun, Arthur Taveras, Deping Wang, Zhili Xin, Lei Zhang
  • Dual encoder
    Patent number: 9560724
    Abstract: A dual encoder (07) has a first shaft (09) being mounted in a housing (16) so as to be rotatable, wherein a first locking mechanism, for locking different rotational positions of the first shaft (09), and at least one first rotation signal generator (26, 27), for generating a signal showing a switchover between two locking positions, are provided at the first shaft (09), and having a second shaft (10) being mounted in the housing (16) so as to be coaxially rotatable, wherein a second locking mechanism for locking different rotational positions of the second shaft (10) and at least one second rotation signal generator (28, 29) for generating a signal showing a switchover between two locking positions are provided at the second shaft (10), wherein both shafts (09, 10) include activation elements (11, 12).
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: January 31, 2017
    Assignee: MA LIGHTING TECHNOLOGY GMBH
    Inventors: Roland Jördens, Michael Adenau
  • Compounds that are S1P modulating agents and/or ATX modulating agents
    Patent number: 9550798
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: January 24, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur Taveras, Zhili Xin, Lei Zhang
  • BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
    Patent number: 9545086
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: January 17, 2017
    Assignee: Biogen MA Inc.
    Inventors: Fabienne MacKay, Susan Kalled
  • Methods of treating inflammatory disorders using high concentration natalizumab compositions
    Patent number: 9533044
    Abstract: Formulations of VLA-4 binding antibody are described.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: January 3, 2017
    Assignee: BIOGEN MA INC.
    Inventor: Kevin Maloney
  • Compositions Comprising Antibodies to Lingo or Fragments Thereof
    Publication number: 20160368984
    Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 22, 2016
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Christilyn Graff
  • PRINTED CIRCUIT BOARD VIA FUSE
    Publication number: 20160374203
    Abstract: A printed circuit board (PCB) via fuse including a non-conductive substrate having a pair of terminal conductors, a plurality of jumper conductors and one or more through-hole vias that electrically connect the terminal conductors and jumper conductors. The through-hole vias function as the fuse element of the PCB via fuse.
    Type: Application
    Filed: June 17, 2016
    Publication date: December 22, 2016
    Applicant: Mersen USA Newburyport-MA, LLC
    Inventors: Shashank Bakre, Arthur Gilenberg
  • ATX modulating agents
    Patent number: 9522889
    Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: December 20, 2016
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur Taveras, Deping Wang, Zhili Xin, Lei Zhang
  • Stable liquid interferon beta formulations
    Patent number: 9522174
    Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: December 20, 2016
    Assignee: Biogen MA Inc.
    Inventors: Mary D. DiBiase, Wen-Li Chung, Mark Staples, Eric Scharin
  • METHOD FOR DELIVERING INTERFERON-BETA
    Publication number: 20160361389
    Abstract: The method described herein reduces the amount of aggregating metal released into solutions of Interferon-.beta.
    Type: Application
    Filed: August 25, 2016
    Publication date: December 15, 2016
    Applicant: Biogen MA Inc.
    Inventors: Eric Anthony Faulkner, Mary Diana DiBiase
  • Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of Lingo-1 Antagonists and TrkB Agonists
    Publication number: 20160354465
    Abstract: This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist.
    Type: Application
    Filed: May 16, 2016
    Publication date: December 8, 2016
    Applicant: Biogen MA Inc.
    Inventor: Sha Mi
  • RECOMBINANT FACTOR VIII PROTEINS
    Publication number: 20160355568
    Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.
    Type: Application
    Filed: February 15, 2013
    Publication date: December 8, 2016
    Applicant: BIOGEN IDEC MA INC.
    Inventor: John KULMAN
  • USE OF CATION-EXCHANGE CHROMATOGRAPHY IN THE FLOW-THROUGH MODE TO ENRICH POST-TRANSLATIONAL MODIFICATIONS
    Publication number: 20160347787
    Abstract: The present invention relates to improved methods in the separation recombinant polypeptides with post-translational modifications from complex mixtures through the use of a cation exchange medium.
    Type: Application
    Filed: February 4, 2015
    Publication date: December 1, 2016
    Applicant: BIOGEN MA INC.
    Inventors: Austen NG, Robert S. GRONKE
  • Spectroscopic analysis of nutrient materials for use in a cell culture process
    Patent number: 9506867
    Abstract: In some embodiments, aspects of the disclosure relate to methods of evaluating cell culture materials, for example, nutrient materials, or other materials that can be used in cell culture media.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: November 29, 2016
    Assignee: Biogen MA Inc.
    Inventors: Justin Moretto, Kelly Wiltberger
  • Compounds that are S1P modulating agents and/or ATX modulating agents
    Patent number: 9499485
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: November 22, 2016
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Lihong Sun, Zhili Xin, Lei Zhang
  • Pro-coagulant compounds and methods of use thereof
    Patent number: 9486507
    Abstract: The present invention provides pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. The present disclosure further provides conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates of the present disclosure are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. The present disclosure further provides methods of using and making the conjugates.
    Type: Grant
    Filed: June 9, 2012
    Date of Patent: November 8, 2016
    Assignee: Biogen MA Inc.
    Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
  • Display screen with graphical user interface
    Patent number: D773513
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: December 6, 2016
    Assignee: BIOGEN MA, INC.
    Inventors: Jane Relton Rhodes, Wendy Gabel, Erik Mednis